Eugeniin

Research use only, not for human use.

Tellimagrandin II (Eugeniin), with oral activity, is the first intermediate of the ellagitannin series derived from 4C1-glucose. It inhibits the resistance of Staphylococcus aureus by disrupting the integrity of the cell wall, leading to the loss of cytoplasmic contents. Additionally, Tellimagrandin II exhibits anti-inflammatory effects and inhibits acetylcholinesterase (AChE) activity, improving memory impairment. Tellimagrandin II holds potential for research in the fields of antibacterial, anti-inflammatory, and neurodegenerative diseases.

Tellimagrandin II (Eugeniin), the first intermediate in the 4C1-glucose derived series of ellagitannins, also inhibits antibiotic resistance of drug-resistant Staphylococcus aureus.

Western Blot Analysis Cell Line:Methicillin-Resistant Staphylococcus aureus Concentration:40 μg/mL Incubation Time:5 h Result:Significantly reduced PBP2a protein levels.Real Time qPCR Cell Line:Methicillin-Resistant Staphylococcus aureus Concentration:40 μg/mL Incubation Time:5 hResult:Significantly reduced mecA mRNA expression.Real Time qPCR Cell Line:LPS -induced inflammation RAW264.7 cells (murine macrophages) Concentration:50 μM Incubation Time:6 h Result:Significantly reduced NOS2 gene expression levels induced by LPS .Western Blot AnalysisCell Line:LPS -induced inflammation RAW264.7 cells (murine macrophages) Concentration:25 和 50 μM Incubation Time:12 h Result:Significantly reduced LPS -induced COX-2 protein levels and PGE2 production.

Animal Model:Scopolamine -induced amnesiac ICR mouse model Dosage:100 and 200 mg/kg Administration:Oral gavage (p.o.), once daily for 10 days Result:Improved learning and memory functions in the passive avoidance and water maze tests.

———

Others

Other Targets

———

———

———

81571-72-4

938.665

C41H30O26

>98% (HPLC)

DMSO : 100 mg/mL (106.53 mM; ultraphonic; )

———

——

(-20℃)

With Ice Pack

≥ 2 years